Overview

Radiation Therapy and Combination Chemotherapy for Medulloblastoma

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:
0

Participant gender:
All

Summary

This phase II trial is studying giving radiation therapy together with combination chemotherapy after surgery to see how well it works in treating children with newly diagnosed medulloblastoma.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Dacarbazine
Temozolomide

Criteria

Inclusion Criteria:

1. Histologically confirmed posterior fossa medulloblastoma

2. No residual tumor greater than 1.5 cm^2 after resection by postoperative MRI No tumor
in the spinal or cerebral subarachnoid space by MRI No tumor in the subarachnoid space
by Cerebrospinal fluid (CSF) No failure to perform staging studies (spine MRI and CSF
cytology) preoperatively or postoperatively

3. Must begin radiotherapy on study within 28 days after surgery

Exclusion Criteria:

1. Prior radiotherapy and anti-tumor chemotherapy other than corticosteroids are not
allowed.

2. Patients must begin radiotherapy on protocol within 28 days of completion of surgery.
Exceptions need to be approved by the Principal Investigator.

3. Patients with the following will not be eligible:

> 1.5cm3 residual tumor following resection as indicated by post-operative MRI. tumor in
spinal or cerebral subarachnoid space either by MRI of brain and spine tumor in
subarachnoid space by CSF cytology failure to perform staging studies (spine MRI, CSF
cytology) either pre- or post- operatively